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Abstract: The role of fruits and vegetables in the pr vention and treatment of chronic 
diseases such as osteoporosis are continuously being explored. The purpose of this study 
was to investigate the dose-dependent effects of freeze-dried watermelon in the 
prevention of bone loss in ovariectomized (OVX) mice, a model of post-menopausal 
osteoporosis. We hypothesized that compounds in watermelon such as lycopene and 
citrulline would help prevent bone loss in this animal model. Three month old C57BL/6 
female mice (n=68) were sham-operated or OVX and raomly assigned to treatment 
groups for 12 weeks: sham-control (SHAM), OVX-contrl, OVX + 1%, 10% or 25% 
(w/w) freeze-dried watermelon (WM), or OVX-control with alendronate (OVX-ALN) 
injection (100 µg/kg body weight). All diets were isocaloric, isonitrogenous and had the 
same calcium and phosphorus concentrations. The 25% WM group had significantly 
higher final body weight and % body fat compared to the OVX-control group. The DXA 
scans using PIXImus showed watermelon was not able to prevent the decrease in whole 
body, tibial, and lumbar bone mineral content and density due to estrogen deficiency. 
Micro-computed tomography (µCT) analyses howed no similarities between WM-fed 
groups and SHAM for tibial trabecular and cortical bone microarchitecture. However, the 
lumbar trabecular micro-architecture analyses reveal d that the WM 10% group had 
similar connectivity density to the SHAM group and higher than the other two doses of 
WM and OVX-control groups. Bone volume, structure model index and trabecular 
separation of the WM 10% group are similar to the SHAM and OVX-control groups. 
Watermelon supplementation increased liver catalase mRNA and tended to increase 
plasma glutathione peroxidase activity. Our data indicates that watermelon, in a moderate 
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Osteoporosis is a metabolic bone disease, which increases the risk of bone fractures as 
bone demineralization progresses and is classified as a major public health problem. Overall, 200 
million people in the world have osteoporosis and it has been linked to hormonal and other age 
related physiological changes. It can affect both men and women but it is estimated that 30% of 
all postmenopausal women in the United States and European Union have osteoporosis (1). 
Research shows that the withdrawal of estrogen post menopause can decrease the rate of bone 
formation and anitresorptive drugs and intermittent PTH are commonly used as treatments (2,3). 
In 2005, total costs related to osteoporosis neared 19 billion dollars in the U.S and is projected to 
increase by 50% by 2025 (4). The most common sites aff cted by osteoporosis include the spine, 
hip and wrist, followed by humerus and ribs. Osteopor sis is commonly diagnosed after the 
patient has had their first fracture and therefore, more focus recently is placed on determining the 
risk and preventing the disease (5). 
The human skeleton consists of mainly two types of bone:  about 80% cortical bone and 
20% trabecular bone. Cortical bone is the dense solid part that surrounds the marrow spaces while 
the trabecular bone is described as a honey-comb like structure that fills the marrow space. The 
outer surface of the bone is referred to as the periost al and the inner surface is the endosteal 
surface. As a person ages, their bones increase in diameter due to increased bone formation  
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on periosteal surface and the marrow space expands due to increased bone resorption on the 
endosteal surface. Along with the effects of age on the skeletal system, estrogen withdrawal due 
to menopause causes an increase in bone loss, whichis the major contributor to postmenopausal 
osteoporosis. The cells that are responsible for this p ysiological activity of the bone are called 
osteoblasts and osteoclasts, and osteocytes. Osteoblasts and osteoclasts are associated with bone 
formation and bone resorption, respectively while oste cytes are mature osteoblasts that make up 
majority of skeleton, and are mechanosensory cells involved in the regulating bone turnover (6,7).  
Postmenopausal osteoporosis results when there is an imb lance in the activity of 
osteoblasts and osteoclasts due to the decrease in e trogen production. There are multiple proteins 
such as receptor activator of nuclear factor-κB (RANK), receptor activator of nuclear factor-κB 
ligand (RANKL), macrophage colony stimulating factor (M-CSF), and osteoprotegerin (OPG) 
that influence osteoclast differentiation and activity and are affected by the removal of estrogen 
(5). Osteoclast activity is stimulated through RANKL. RANKL, a member of the tumor necrosis 
factor receptor (TNFR) superfamily, is manufactured in osteoblasts and bone marrow stromal 
cells (T and B lymphocytes) and interacts with its receptor, RANK, on osteoclasts and 
hematopoietic precursors cells to mediate cell resorption by controlling the transcription of DNA 
for cell differentiation and resorption (5,8). Macrophage colony-stimulating factor (M-CSF) and 
RANKL are the essential cytokines required for osteclast formation under basal conditions (9). 
M-CSF, secreted by osteoblasts, interacts with its receptor c-Fms and stimulates proliferation of 
preosteoclasts while RANK found on progenitor cells bind to RANKL to produce mature 
multinucleated osteoclasts and also act on osteoclasts to increase bone resorption (5). 
Osteoprotogerin (OPG) is part of the TNF superfamily and is a soluble decoy ligand for RANK 
that inhibits osteoclasts activity (10).  OPG originates from many cells including osteoblasts, 
heart, liver, kidney and spleen. The ratio of RANKL to OPG is one of the factors that determine 
the osteoclasts activity (11).   
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There are several factors that may influence the lev ls of RANKL and OPG including 
hormones, growth factors, inflammatory cytokines, and genetic polymorphisms, and vitamins 
such as Vitamin D. Estrogen has been linked to increased OPG and decreased RANKL secretion 
(12). Studies have shown that chronically elevated parathyroid hormone (PTH) increases bone 
resorption in a dose-dependent manner (13). Growth fac ors that may play a role in regulating 
bone formation and resorption include insulin-like growth factor 1 (IGF-1) and transforming 
growth factor-β (TGF-β). Cytokines are also major pathway regulators of the RANKL/OPG 
system. Some of the cytokines that promote bone resorption include interleukin 1 (IL-1), IL-6, 
IL-7, IL-17, and TNF-α. On the other hand, cytokines IL-4, IL-13 and interferon-γ are associated 
with suppressing the formation of osteoclasts (14). Estrogen deficiency promotes TNF producing 
T-cell activation in the bone marrow and thereby causing an increase in TNF-α production (9). 
TNF-α increases RANKL production and increases the responsiveness of osteoclasts precursors 
to RANKL. This cytokine also increase osteoclast activity and inhibit osteoblast production (15). 
Inflammatory cytokines can also trigger the production of reactive oxygen species (ROS), which 
can increase the transcription of RANK and thereby increase osteoclast formation and activity 
and decrease osteoblasts by promoting apoptosis (16). Together inflammation and increase 
oxidative stress lead to the progression and exacerb tion of osteoporosis unless there is a 
treatment intervention.  
Common drug treatment options available for osteoporosis include bisphosphonates and 
intermittent PTH. Bisphosphonates that work by decreasing osteoclasts-related bone resorption 
include drugs such as alendronate, risedronate, ibandronate, and zoledronic acid (17).  However, 
these treatments have low compliance rates as well as unpleasant side effects including nausea, 
abdominal pain, esophagitis and esophageal ulceration (3). Hormone replacement therapies 
(HRT) have been linked to increased blood clots, heart disease, and breast and endometrial cancer 
(18). According to a follow up study, 1,000 postmenopausal women, the use of HRT declined by 
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12% from 2003 to 2004 (19). 1 in every 4 women using hormone replacement therapy, and 1 in 
every 5 women using alendronate, discontinued its use due to side effects including breast 
tenderness, menstrual bleeding, and hot flashes for hormone replacement therapies and GI 
distress for alendronate (18).   
To reduce the effects of, or prevent osteoporosis, it is important to decrease the 
inflammatory and oxidative stress pathways that lead to the increased bone resorption and 
decreased osteoblast number and activity. Fruits and vegetables are beneficial in maintaining 
skeletal health is because they contain bioactive compounds that have anti-inflammatory and 
antioxidant properties (20). Among the variety of fruits, watermelon because of its active 
compounds, may play a role in maintaining skeletal he lth (21). Some of the bioactive 
compounds in watermelon include vitamin C, β-carotene, potassium, phenolic compounds (e.g. 
flavanoids, carotenoids, and triterpenoids) and citrulline. Lycopene is a well-known antioxidant 
and recent studies suggested that lycopene may actually increase osteoblast proliferation and 
decrease PTH stimulated osteoclast development and proliferation (22,23). Studies with 
postmenopausal women demonstrated that those who took lycopene supplements had much lower 
serum oxidative stress ( such as catalase and superoxid  dismutase) and bone resorption markers 
(such as crosslinked N-telopeptide of type I collagen) (24,25,26). An analysis of the Framingham 
osteoporosis study showed a relationship between increased carotenoid, such as β-carotene, and 
lycopene intake and reduced risk of hip fracture (27). In addition to lycopene, watermelon 
contains carotenoids and vitamin C as well as the amino acid (more concentrated in the rind) 
citrulline, which is converted into arginine in the body.  The demand for arginine is increased 
when macrophages respond to inflammation, therefore inc asing the body’s physiological needs, 
which can be provided through metabolism of citrulline (28). Watermelon may help in the 
prevention of inflammatory-related conditions such as osteoporosis by providing citrulline, which 
can be converted to arginine. 
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Although lycopene, vitamins C, β-carotene as well as citrulline have been shown to have 
anti-inflammatory and antioxidant properties, we arnot aware of studies investigating the effects 
of freeze-dried watermelon fruit on skeletal health nd clinical parameters. Therefore, the 
objective of this study was to determine the extent to which watermelon would be able to prevent 
bone loss and attenuate clinical parameters, such as glucose and lipids, in ovariectomized mice, 
an animal model for postmenopausal osteoporosis. Due to the antioxidant and anti-inflammatory 
properties of the bioactive compounds in watermelon, our null hypotheses are that freeze-dried 
watermelon dose-dependently will have no effects on: 
1. bone mineral density, 
2.  bone microarchitecture, 
4. clinical parameters (i.e. glucose and lipids), and







REVIEW OF LITERATURE 
 
Bone Function and Structure 
The skeletal system is designed to provide a variety of important functions. Some of 
these functions include structure, movement, protecti n, mineral homeostasis, acid-base balance, 
a reservoir of growth factors and cytokines, and hematopoiesis, as well as serving as an important 
immune function regulator (5,6). All of these vital ro es are what makes it extremely important to 
keep the skeletal system healthy.  
The human skeleton is primarily comprised of two major types of bone, cortical and 
trabecular. Cortical bone that makes up about 80% of all bone is the dense solid portion of the 
bone that surrounds the marrow space. Trabecular bone is a network of plates and rods within the 
marrow space that creates a honey-comb like appearance. The cortical bone is made up of the 
periosteal and endosteal surfaces. The periosteal surf ce is the outer part of the cortical bone 
where bone formation is greater than bone resorption. It is a network of fibrous connective tissue 
that contains blood vessels nerve fibers, osteoblasts and osteoclasts, and can be found on all 
bones except at joints. The inner endosteal surface of the cortical bone that surrounds the marrow 
space and trabecular bone, undergoes more bone resorption than bone formation (6).  This change 
in bone structure leads to the increases in bone diameter and expands the marrow space with age, 




At the cellular level bone is composed of three major cells, osteoblasts or bone forming 
cells, osteoclast or bone resorbing cells and osteocy s, which are mature osteoblasts. For bone 
remodeling to occur there must be communication betwe n these three cells also known as “bone 
coupling”. Bone remodeling is an intricate process that involves osteoclasts resorbing bone at a 
particular location and osteoblasts forming new bone ver that area. Osteocytes are thought o be 
involved in initiating the bone remodeling process a  well as terminating it (40). The health of the 
bone is a direct consequence of the communication between the three cells to maintain a balance 
in bone formation and resorption.  At any given moment, 20% of trabecular bone is constantly 
undergoing remodeling in the body (29).   
Osteoclast Function 
Osteoclasts are formed from hematopoietic precursor cells that are stimulated to 
differentiate by binding of RANKL to RANK and the presence of M-CSF. Osteoblasts secrete 
RANKL, M-CSF as well as OPG, a decoy receptor for RANKL that inhibits osteoclastogenesis. 
RANKL is also secreted in large quantity by activated T-cells that also produce TNF-α in 
abundance. TNF-α binds to its receptors, p55 and p75, on osteoclasts as well (30). The binding of 
RANKL to RANK, M-CSF to c-Fms, and TNF-α to p55/p75, on the osteoclasts and osteoclasts 
precursors stimulates a cascade of intracellular events. This includes the mobilization of TNFR-
associated factor proteins (TRAF), which leads to the activation of NF-κB, a transcription factor, 
and also c-Jun NH2-terminal kinase (JNK), thus increasing expression of genes needed for 
osteoclastogenesis (31). It is not understood how osteoclasts recognize the sites that need to be 
resorbed however it has been suggested that osteocytes are responsible for sensing micro 
fractures in the bone and send signals to the osteoclasts progenitor cells (30, 40). Osteoclasts 
travel to the site that needs to be resorbed and attach o the surface using their extremely agile 
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cytoskeleton and β1 integrins to form a barrier from the bone to be resorbed and the outside 
environment (30). Osteoclasts create a tightly sealed cidic environment using a polarized 
vacuolar proton pump, H+–adenosine triphosphatase bringing it to a pH of -4.5 (5,32).  The acidic 
environment first causes the bone to demineralize leaving the organic component to be degraded 
by cathepsin K, a lysosomal protease released into the extracellular space on the apical side. The 
osteoclasts endocytose the degraded products then release it on its basolateral side (33). The 
degraded products released include insulin-like growth factor (IGF) and transforming growth 
factor-β (TGF-β), which will draw in the osteoblasts to form new bone (5).  
Osteoblast Function  
Osteoblasts are formed from pluripotent mesenchymal stem cells located in the bone 
marrow (34). Differentiation is stimulated by runt-related transcription factor 2 (Runx2), an 
important transcription factor that form preosteoblasts. In the presence of osterix (OSX), another 
important transcription factor, the preosteoblasts turn into mature osteoblasts (35). Alkaline 
phosphate (ALP), a protein required for mineralization of bone, and type 1 collagen are needed 
before bone formation takes place (36,37,38). At the molecular level, one of the most important 
factors regulating osteoblast differentiation is dependent on the stimulation of the canonical Wnt/ 
β-Catenin pathway (39). When the Wnt family of protein associate with their receptors, mainly 
Frizzled and (LDLR)-related protein 5 (LRP5), it ses off a signaling cascade that allows β-
Catenin to be dephosphorylated and inhibit glycogen synthase kinase 3β (GSK-3β) activity, the 
main kinase responsible for phosphorylating β-Catenin . The dephosphorylation of β-Catenin 
allows it to translocate into the nucleus and promote the transcription of genes responsible for 
osteoblastogenesis (39). After successful differentiation, osteoblast move into the lacunae formed 
by osteoclasts. In the presence of mineralization factors such as vitamin D, calcium and 
phosphate, osteoblasts start to release components for the extracellular matrix that includes type I 
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collagen and other non-collagenous proteins, such as osteocalcin, osteonectin, and osteopontin 
(37,39).  
Osteocyte Function  
Once the osteoblasts have rebuilt the resorbed area, they transform into bone cells, or 
osteocytes, which account for about 90% of all bone cells (5).  Osteocytes are thought to be the 
major bone cell that responds to mechanical loading. Increased mechanical load has been 
suggested to stimulate bone formation and decreased load stimulates bone resorption.  These cells 
have unique dendritic processes that allow them to communicate with each other and other cells 
in the bone (40). Osteocytes are able to regulate osteoclastogenesis through expressing increased 
RANKL on their dendritic processes (41). Additionally, osteocytes are capable of regulating 
osteoblastogenesis by releasing sclerostin, which inhibits the Wnt/ β-Catenin pathway discussed 
earlier (42). The completion of the bone remodeling process leads to new bone if there is a 
balance between the functions of the bone cells. When estrogen is removed as in the case of a 
postmenopausal woman, these processes are altered leading to the development of osteoporosis.  
Osteoporosis  
Osteoporosis is a major health concern as the resulting fractures lead to a reduced quality 
of life, a decline in independence, and maintenance of overall health. Osteoporosis places a great 
economic burden on healthcare costs. It is estimated that by 2020, greater than 14 million people 
will have osteoporosis in the United States (4). Along with this, in 2005, the estimated cost of 
osteoporosis in the U.S was between 13.7 to 20.3 billion dollars and this has only been projected 
to increase (43). Costs were substantially increased in women with increasing age with 89% of 
costs belonging to women over 65 years of age (4).  A study in 1997 by Hoerger and colleagues 
(44) of women over the age of 45, found that postmenopausal osteoporosis accounted for 12.9 
billion dollars in total healthcare costs. The most common fracture sites in this disease include 
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vertebra, hip, wrist and pelvic bones (5). Vertebral fractures accounted for 27% of total fractures 
from osteoporosis followed by wrist (19%), hip (14%), and pelvic (7%); however, hip fractures 
produced the most health care costs (4).  
The World Health Organization (WHO) has developed diagnostic criteria for osteopenia 
and osteoporosis. The classification of the disease is relative to the average BMD of a 30-year-old 
adult, and the severity depends on the number of standard deviations away from the reference 
value, also called a T score. “Normal” is defined as a T score of greater than -1.0, osteopenia is 
between -1.0 to -2.5, osteoporosis is below -2.5, and established osteoporosis is defined as a score 
below -2.5 plus a fragility fracture. A Z-score, whic  matches for age and gender, can also be 
used to diagnose postmenopausal osteoporosis (45).   
Treatment Options  
Pharmacological treatment options available to women inflicted with postmenopausal 
osteoporosis include drugs that have antiresorptive effects and also drugs that have anabolic 
effects. Dunosumab, bisphosphonates, calcitonin, and estrogen agonists/antagonists are classified 
as antiresorptive drugs. Bisphosphonates include the drugs alendronate, ibandronate, risedronate, 
and zoledronic acid. Raloxifene is an estrogen agonist/a tagonist that is not a hormone, but 
provides the beneficial effects of estrogen. Treatmnts that have an anabolic effect or those that 
stimulate bone formation include teriparatide parathyroid hormone, which is a recombinant PTH 
hormone fragment (46).    
Bisphosphonates work to decrease bone resorption by inhibiting osteoclast recruitment 
and adhesion and also decreasing their lifespan and activity (47). Denosumab is an antibody 
specific for RANKL, which binds to RANKL to prevent its interaction with its receptor RANK. 
This leads to decreased osteoclast differentiation and activity and thereby leading to decreased 
bone resorption (48). Based on clinical trials, Denosumab administered subcutaneously twice a 
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year for 36 months significantly decreased the risk of fractures and also increased BMD 
compared to alendronate (49,50).  Multiple side effcts were recorded during clinical trials for 
Denosumab and bisphosphonates including nasopharyngitis, back pain, bronchitis, arthralgia, 
constipation and pain in extremities (51). McCombs et al., using data from a large health insurer 
discovered that the one-year compliance rates for osteoporosis therapies, bisphosphanates, 
raloxifene, and hormone replacement therapies, wereless than 25% (55). Another study 
conducted by Yood et al., interviewed 176 patients just starting any sort of therapy, and found a 
compliance rate of 70.7% with bisphosphonates therapy and 69.3% with estrogen therapy after 
one year or later (56).   
Raloxifene acts as a selective estrogen receptor modulat r and is able to increase BMD 
without increasing risk of breast cancer, like estrogen might possibly do (52). However it also has 
undesirable side effects such as thromboembolic events and neuro-emotional events such as 
nervousness, insomnia and emotional instability (53). Teriparatide is a recombinant parathyroid 
hormone fragment that has been shown through phase III clinical trial to reduce fracture rates in 
elderly women who have already experienced a fractue, and is generally used as a last resort for 
patients with severe osteoporosis because of the high cost and side effects such as leg cramps and 
dizziness (46, 54).  
Because of the increase population at risk, specifically post-menopausal women, the great 
economic burden, and the side effects and decreased compliance rates of prescription drugs, it is 
necessary to place an importance in research for prevention and treatment of the disease to 
decrease risks and health care costs (57).  
Role of Estrogen in Development of Postmenopausal Osteoporosis 
Estrogen is a hormone that is widely known for its ole in the female reproductive system 
and sexual characteristics but it is also important in males for spermatogenesis and fertility  (58). 
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Estrogen is also vital in maintaining bone homeostasi  in both genders, and when removed in 
women post menopause, sometimes results in osteoporosis. Estrogen receptors are found on both 
cortical and trabecular bone, however trabecular bone tends to have a higher expression of 
estrogen receptor-β , and cortical bone tends to express more estrogen receptor-α. It has been well 
documented that estrogen withdrawal due to menopause causes a decrease in bone mass (59). 
After menopause, the amount of osteoclasts in trabecular bone increases and the rate at which 
women experience bone loss increases by 10-fold (34).  
Estrogen withdrawal affects bone resorption and formation through many different 
mechanisms. Estrogen deficiency has been linked to increased bone resorption by increased 
osteoclast formation, recruitment, and lifespan (by reducing apoptosis) (9). Estrogen deficiency is 
also responsible for decreased bone formation through increased osteoblast apoptosis and by 
limiting the activity of mature osteoblasts (9). All of these actions together increase the activation 
and frequency of basic multicellular units (BMU), the anatomical space which harbor the 
activities of osteoblasts and osteoclasts combined, i crease remodeling space, cortical porosity, 
resorption area of trabecular bone, and erosion depth (59).  
The mechanism of action through which estrogen withdrawal exhibits its effects is 
mainly through increased inflammation and oxidative str ss (9). Estrogen deficiency increases 
inflammation is through promotion and inhibition of in lammatory cytokine genes, specifically 
TNF-α, IL-6, and M-CSF. When the estrogen receptor becoms activated it is able to bind to NF-
κB and prevent the transcription of IL-6 genes. Similarly, activated estrogen receptor decreases 
JNK activity, which leads to decrease in activator protein 1, reducing the production of TNF-α 
genes (60). The withdrawal of estrogen would then lead to an uncontrolled production of these 
cytokines. Another main effect of estrogen withdrawal is the increase in TNF producing T-cells 
(61,62). Under normal conditions, estrogen balances th  production of IL-7 by increasing TGF-β 
gene expression. Without this effect of estrogen, there is an increase in IL-7 production, which 
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stimulates TNF producing T-cell activation and expansion from the thymus and travels to the 
bone marrow. Effects of estrogen deficiency on IL-7 production is also seen directly in the bone 
marrow, where it increases hematopoietic stem cellsturn into lymphoid progenitors, which will 
consequently increase thymic output of T-cells (9,61). Estrogen deficiency causes bone loss by 
increased inflammation which leads to increased osteoclast- mediated bone resorption by direct 
effects on osteoclasts, and indirect effects by activ ting RANKL and decreasing OPG production 
(63,64).   
ROS have also been implicated in the development and progression of postmenopausal 
osteoporosis (65). Another important role for estrogen in the body is that it exhibits antioxidant 
activity by increasing the expression of glutathione peroxidase in osteoclasts. The increase 
production of glutathione peroxidase neutralizes hydrogen peroxide produced by osteoclasts, 
which is needed in the bone resorption process (66). Along with this the production of ROS 
decreases osteoblast lifespan and disrupts the procss of bone formation, by decreasing 
differentiations of progenitor cells (36). Together inflammation and oxidative stress create an 
environment that feeds bone resorption mechanisms and blocks bone formation. The following 
sections take in depths look at the mechanisms behind t e harmful effects of inflammation and 
oxidative stress on bones.  
Role of Inflammation  
A relationship between age-related inflammation and the development of osteoporosis 
also exists (67).  Chronic secretion of inflammatory cytokines take part in the development and 
progression of postmenopausal osteoporosis. In addition to RANKL, specific pro-inflammatory 
cytokines such as IL-1, IL-6 and TNF-α have been shown to take part in the bone remodeling 
process as well as in the development of postmenopausal osteoporosis through the withdrawal of 
estrogen. Age, as well as impaired immune function contribute to the release of pro-inflammatory 
cytokines and thus to the progression of osteoporosis (67).  
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As discussed earlier, estrogen deficiency leads to increased production of TNF-α by up-
regulating gene expression through reducing the corpressor complexes that limit gene 
expression, and also through increasing activated TNF producing T-cells. TNF-α is the most 
effective inflammatory cytokine that increases osteclasts differentiation and activation. Ritchlin 
et al. (68) demonstrated that mice overexpressing TNF-α, or mice injected with TNF-α showed an 
increase in osteoclast precursors. TNF-α also decreases osteoblast activity and increase RANKL 
secretion by macrophages through stimulating gene expression (15). TNF-α participates in 
intracellular mechanisms closely related to RANKL to activate NF-κB and therefore increase 
osteoclastogenesis. TNF-α interacts with two different cell receptors on thepr osteoclasts and 
osteoclasts: TNF-α receptor one (TNFRI) and TNF-α receptor two (TNFRII). These two 
receptors have different functions. When a soluble form of TNF-α interacts with TNFRI it 
recruits proteins that induce apoptosis. At the same ti e, TNFRI is also involved in the pathway 
that activates NF-κB, which produced an anti-apoptosis effect. Membrane bound TNF-α 
interacting with TNFRII acts only through intracellular mechanisms that activate NF-κB and 
promote osteoclastogenesis (69).  
Estrogen deficiency also affects the production of other inflammatory cytokines such as 
IL-1 and IL-6 resulting to increased bone loss. IL-1 and IL-6 are two other powerful 
inflammatory cytokines that can promote bone loss and are also induced by estrogen withdrawal. 
IL-1 takes part in osteoclastogenesis by the activation of NF-κB and is also released in response 
to TNF-α (69). IL-1 has also been shown to increase RANK-L mRNA steady state levels in 
osteoblasts, therefore stimulating osteoclastogenesis (70). IL-6 on the other hand, secreted from 
osteoblasts and stromal cells, works to increase bon  resorption by promoting osteoclast 
differentiation and activation. Most of the inflammatory effects of IL-6 occur through its effects 
in increasing other bone resorbing inflammatory cytokines like TNF-α and IL-1 (69). All of these 
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increases in inflammatory cytokines leave an imbalance between osteoblast and osteoclasts 
activity, while promoting oxidative stress also.  
Role of Oxidative Stress 
Oxidative stress, which is due to accumulation of ROS, is linked to osteoporosis (36) 
ROS can be produced in numerous locations in the cell in luding cytoplasm, endoplasmic 
reticulum, mitochondria and cell membrane (36). Once ROS are produced, they start a cycle of 
cell destruction affecting the lipid membranes, proteins and DNA, which can contribute to 
osteoblast apoptosis (36,71). Along with direct effects of ROS on cells, they disrupt signaling in 
bone coupling that occurs during the bone remodeling process by decreasing bone formation and 
increasing RANK-L production (36).   
 The decreased bone formation rate and bone mineral d nsity (BMD) in osteoporosis has 
been linked to increased levels of pro-oxidants or decreased levels of anti-oxidants in the body 
(72,73,74). Estrogen acts like an antioxidant for oste clasts by mediating the production of the 
glutathione peroxidase. The removal of estrogen not o ly diminishes a molecule in the body with 
antioxidant effect but also stimulates the body to pr duce reactive oxygen species (ROS) 
specifically hydrogen peroxide and superoxide anion (66). ROS that are not reduced by molecules 
with antioxidant effects such as estrogen increase lipid accumulation, which in turn increases 
osteoblasts apoptosis (36). The process of programmed cell death produces its own set of ROS. 
Along with estrogen’s role in producing ROS, inflammatory cytokines can also stimulate their 
production (75,76,77).  
Studies have suggested that osteoclasts use hydrogen peroxide to facilitate in bone 
resorption (77,78). Glutathione peroxidase, which is responsible for the degradation of hydrogen 
peroxide, is found in large amounts in osteoclasts, po sibly as a protective mechanism for the cell, 
and for regulation of bone resorption. Estrogen as mentioned earlier, is one of the factors that 
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mediate the expression of glutathione peroxidase in osteoclasts (66). The increased amount of 
ROS from estrogen withdrawal increases TNF-α activity, which in turn activates NF-κB for 
osteoclastogenesis. Osteoclast formation through the RANK-L/RANK system requires ROS 
production to function, and similarly RANK-L production in osteoblasts is increased in response 
to ROS (36,79,80).  
ROS can also contribute to osteoporosis through the disruption of bone formation by 
diminishing differentiation of progenitor cells into osteoblast and once formed, by decreasing 
osteoblasts lifespan (36). Runx2, an important transcription factor, and alkaline phosphate (ALP), 
a protein required for mineralization of bone, colony-forming units osteoblast (CFU-O), and type 
1 collagen are some of the key components involved in the osteoblasts differentiation process (36, 
37,38). Bai et al. (37) showed that hydrogen peroxide was able to significantly reduce ALP 
activity, CFU-O formation, expression of type 1 collagen, and phosphorylation or activation of 
Runx2. Another mechanism by which ROS acts on osteoblasts is by reducing its lifespan (36). 
Increased ROS inside an osteoblasts will induce apoptosis, however osteoblasts generally have a 
protective mechanism in place through the protein glutaredoxin 5 (Grx5). Grx5 is able to reduce 
the ROS inside the cell mainly by reducing the action of manganese superoxide dismutase (36). 
Together the research on the harmful effects of ROS suggests a vital role for estrogen in 
maintaining bone health. Reducing inflammation and oxi ative stress would be good preventative 
strategy for women inflicted with postmenopausal oste porosis.  
Inflammation and ROS are clearly implicated in the development and progression of 
postmenopausal osteoporosis and provide direction for prevention and treatment therapies. Fruits 
and vegetables have many bioactive components that have antioxidant and anti-inflammatory 
properties and therefore may be beneficial in bone health (20). This thesis will focus on how 
watermelon because of its bioactive components discussed in detail below, could possibly be a 





In 2010, watermelon (Citrullus lanatus) was produced at 4.1 billion pounds in the United 
States and a report from 2008, states American’s ate 15.4 pounds per capita of fresh watermelon 
(81). Watermelon is an important crop in the United States as it bought in $492 million dollars in 
sales in 2010 (81). The commonly ingested portion of watermelon is the flesh, however the rind 
contains nutrients as well. In one cup of fresh watermelon flesh (no rind) there is 46 calories with 
about 0.2 grams of fat, 0.9 grams of protein, and 11.5 grams of carbohydrates. It has about 0.61 
grams of dietary fiber and 139 grams of water, which is approximately 92% by weight. 
Watermelon contains important nutrients that can affect bone health including lycopene, β-
carotene, vitamin C, cucurbitacin E, and an amino acid citrulline (82,83).  
Lycopene  
Lycopene is one of the most potent antioxidants in he human body that has a high singlet 
oxygen (O2) quenching ability, two times higher than β-carotene and ten times higher than α-
tocopherol (84). Animals including humans are unable to synthesize lycopene but plants and 
microorganisms can, therefore we obtain it from our diet. The lycopene content of watermelon 
has been reported to be between 23.0 to 72.0 µg/g wet weight (85). In plants, lycopene absorbs 
light from the sun to protect the plant from photosen itization. It belongs to the family of 
carotenoids whose basic structure is a polyisoprenoid with a long chain of double bonds in the 
center of the molecule. There is almost a perfect symmetry at the center of a carotenoid, around 
the central double bond (86). Unlike other carotenoids, lycopene is not a vitamin A precursor 
because it does not have a β-ionic ring structure at the ends of the hydrocarbon chain (85). It is 
responsible for the red color of the flesh of the fruit, therefore, a more ripened fruit and more 
colorful varieties of watermelon, have high lycopene content (87). 
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Lycopene is a lipid soluble compound and so it is incorporated in fat micelles and 
transported across the intestinal membrane through passive diffusion. Lycopene continues to 
follow the fat digestion process by being packaged into chylomicrons in the enterocytes and then 
transported through the lymph system. Lycopene was found to be concentrated in VLDL and 
LDL and not in HDL. It is transported into tissues that express lycopene receptors including 
testes, adrenal gland, and liver (85).  
Previous studies have shown lycopene to be beneficial for decreasing the effects of 
osteoporosis mainly through its antioxidant effects (27,84). However, lycopene has other non-
oxidative functions that may be important in bone health, which include inhibiting insulin-like 
growth factor-I (IGF-I) signaling and IL-6 expression, increasing oxidative defense, and 
improving the immune response (85). Mackinnon et al. (24) demonstrated that women who took 
lycopene supplements had much lower serum oxidative s ress markers and bone resorption 
markers. Studies have shown that increased intake in elderly men and women of carotenoids and 
lycopene decreased risk of hip fracture and also increased bone mineral density (27,88). Rafi et 
al. (89) demonstrated that lycopene is also involved in ecreasing inflammation by mediating 
nitric oxide production, through regulating nitric oxide synthase, in LPS-induced mouse 
macrophages.     
β-carotene 
In addition to lycopene, another carotenoid found in watermelon is β-carotene. The 
content in red watermelon is greater than or equal to 32.2 µg/100 g wet weight and is considered 
a fruit high in β-carotene (90). β-carotene has a similar structure to lycopene however it has a β-
ionone ring structure at each end, which allows it to be a precursor for retinol (85). β-carotene 
needs to be enzymatically digested before it is absorbed because it forms a complex with proteins 
in food sources. Because it is lipid soluble, it isncorporated into fat micelles for absorption by 
passive diffusion or possibly by a carrier protein scavenger receptor class B type 1 (SR-B1) (91). 
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Within the enterocyte β-carotene is converted into retinol by β-carotene 9’ 10’ dioxygenase or by 
β-carotene 15,15’ –mono-oxygenase (92). Not all β-carotene is converted into retinol and the 
amount that is converted has an efficiency rate of 50% (12 µg of β-carotene is equivalent to 1 µg 
of retinol). The amount of β-carotene converted into retinol in the liver depends on the body’s 
physiological need and the rest of the β-carotene is delivered throughout the body via 
chylomicrons for storage and utilization in other tissues (91). Whatever is not taken up by tissues 
returns to the liver with the chylomicron remnant, and the liver can incorporate it back into 
VLDL for circulation or convert it into vitamin A (91).  
Vitamin A produced from β-carotene has a variety of functions in vision, cell growth and 
differentiation, and gene expression (91). However th e is also some data that suggests that 
Vitamin A may play a role in bone health because excess intake was related to decreased bone 
mineral density and deficiency was related to increased mineral deposition of bone (91). β-
carotene on the other hand may help with bone health by functioning as an antioxidant (91,92). 
Once inside the target tissue, it can be incorporated into the inner surface of the cell membranes 
and has the ability to quench oxygen singlet molecules and neutralize free radicals. β-carotene is 
thought to work in conjunction with vitamin E, whic functions primarily on the outer surface of 
the membrane. β-carotene has the ability to neutralize singlet oxygen molecules, created by 
membrane lipid peroxidation, and also specially interacts with peroxyl radicals (91, 92).  
Along with the studies that demonstrated the positive antioxidant effect of β-carotene on 
bone health (27, 88), Helden t al. demonstrated that a β-carotene-rich diet suppressed 
inflammation in 15,15′-monooxygenase 1 knockout (Bcmo1−/−) animal model (93). This suggests 
a possible role of β-carotene and vitamin A as anti-inflammatory agents as well as antioxidants in 





 Vitamin C (ascorbic acid) is another potent antioxidant found in watermelon. The vitamin 
C content of watermelon has been reported to be about 12.3 mg per cup (152.0 g) of fresh fruit 
(83). Although this is only about 20% of the daily value, 1 cup of watermelon only contains about 
46 calories making each calorie rich with vitamin C (82). Humans cannot synthesize vitamin C so 
it must be consumed in the diet. Vitamin C is a water-soluble molecule that can be absorbed by 
the enterocytes through the sodium dependent vitamin C transporters 1 and 2 (SVCT 1 and 2) or 
if it is in the oxidized form of dehydroascorbate, through GLUT 1. It is then transported in the 
blood in its free form to tissues that require it (91).  
 Vitamin C has a variety of functions in the body including carnitine synthesis, tyrosine 
synthesis and catabolism, microsomal metabolism, and neurotransmitter synthesis (91). A very 
important function of vitamin C that is required for bone formation is collagen synthesis. 
Collagen is synthesized through hydroxylation reactions using prolyl and lysyl hydroxylase, 
enzymes that require the reduced form of iron to function and vitamin C is necessary to reduce 
iron back into its ferrous state (91). Ascorbic acid has been linked to increased rates of both 
procollagen hydroxylation and secretion from osteoblasts (94). Because it is water soluble, it can 
function in aqueous solution making it distinct from lycopene and β-carotene. In the ascorbic acid 
form, it has the potential to donate hydrogen to neutralize free radicals and interact with other 
important antioxidants such as vitamin E and gluthathione (91). Ascorbate perioxidase is an 
enzyme that converts hydrogen peroxide into water and oxygen while simultaneously creating 
oxidized vitamin C. Glutathione is important in reducing dehydroascorbate back into its 
functional ascorbic acid antioxidant form (91, 94).   
 Several studies have suggested that vitamin C may potentially play role in bone health 
and a deficiency could possibly be a risk factor for osteoporosis (95, 96).  A study showed direct 
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effects of vitamin C on osteoblast differentiation through the stimulation of nuclear factor-E2-
related factor-1 on bone marrow stromal cells (97). An in vivo study conducted on a mouse model 
by Gabbay et al., demonstrated that a knock out of the genes that produce vitamin C in mice 
caused severe osteopenia (98). A human study conducted by Leveille et al., on postmenopausal 
women found that increase vitamin C from dietary intake was not related to increased hip bone 
mineral density. However, vitamin C supplementation (113 mg/day) in women aged 55-64 years, 
that had never used HRT, did have beneficial effects on their hipbone mineral density (99). A 
combination of cell, animal and human studies all suggest a positive role for vitamin C in 
increasing bone health (95, 96).  
Other Potential Bioactive Compounds  
Cucurbitacin E, a phytonutrient belonging to the triterpenoid family, is another anti-
inflammatory and antioxidant molecule found in waterm lon (100). Their biological functions 
stems from their highly oxygenated tetracyclic structure. There are no studies to date that show a 
relationship of this phytonutrient to bone health, however a study done by Tannin-Spitz e  al., 
showed that cucurbitacin E had a dose-dependent reduction capacity and inhibition of oxidation 
in cells (100). Watermelon also contains the unique amino acid citrulline that serves as a 
precursor for arginine, an amino acid that is required by macrophages during an inflammatory 
response (28). Arginine is able to control endothelial function, leukocyte activation, innate 
immunity, and extracellular matrix remodeling. During an inflammatory response, arginine is 
quickly used up and becomes conditionally essential. Because of this conversion, citrulline may 
be beneficial as an anti-inflammatory agent (28). Studies have also shown that citrulline is able to 
increase production of nitric oxide in the body therefore being beneficial for vasodilation and 
cardiac health (101). The antioxidant and anti-inflammatory functions of this nutrient could 
possibly be beneficial in postmenopausal osteoporosis, although no direct connections have been 
made to date.  
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All of these bioactive components from watermelon cmbined, lycopene, β-carotene, 
vitamin C, Cucurbitacin E and citrulline, can potentially exert anti-inflammatory and antioxidant 
effects in postmenopausal women. This thesis using varying doses of watermelon looks at the 
extent to which it may be able to provide beneficial effects for skeletal health. Additionally, we 









Diet Formulation and Preparation  
 The dietary treatments for this study were control (AIN-93M), 1% (w/w) watermelon 
(WM), 10% (w/w) WM, and 25% (w/w) WM. Watermelon was obtained from a local 
supermarket, the  rind was removed, and the remaining pulp was freeze-dried. The freeze-dried 
watermelon pulp was incorporated into the AIN-93M diet formulation (102). All diets were 
isocaloric, isonitrogenous and had the same calcium, phosphorus and fiber content (Table 1) and 
prepared at Harlan Laboratories (Madison, WI).  Macronutrient, energy as well as calcium and 
phosphorus content of the diets were analyzed at N.P Analytical Laboratories (St. Louis, MO, 
Table 2). 
Animal Care and Necropsy 
For this study, 8-week-old C57BL/6 female mice were purchased from Charles River 
Laboratories (Chicago, IL). The mice were housed in plastic cages and kept on a 12 hour light: 
dark cycle (7 AM- 7 PM) in a temperature and humidity controlled room and allowed to 
acclimate into this environment for one week. During the acclimation period, mice were given ad 
libitum access to the AIN-93M control diet and deionized distilled water. After the acclimation 
period, mice were weighed and either ovariectomized (OVX) or sham-operated (Sham), and
24 
 
randomly assigned to one of six treatment groups (n=9-13/group): sham-control, OVX-control, 
OVX-1% WM, OVX-10% WM, OVX-25% WM, or OVX-control-alendronate (ALN)  
Mice in the OVX-control-ALN group were given alendronate injection (100 µg/kg body 
weight) once a week. Animals were group housed (3-5 mice/cage) and fed their respective diets 
for twelve weeks. Food intake was measured every three days and body weights were monitored 
weekly. Feces were collected on the 11th and 12th week of the treatment for lipid analyses. 
Guidelines for the ethical care and treatment of anim ls from the Animal Care and Use 
Committee at Oklahoma State University were strictly fo lowed. 
 After 12 weeks of dietary treatment, the mice were sacrificed and specific tissues were 
harvested. The mice were anesthetized with ketamine/xylazine cocktail (100.0/10.0 mg/kg body 
weight) and body composition was assessed by GE Lunar Piximus with Series Software version 
1.4x (GE Medical Systems, LunarPIXI, Madison, WI). Blood samples were obtained from the 
carotid artery and placed into ethylenediaminetetraacetic acid (EDTA) coated tubes. Plasma was 
separated by centrifugation at 1500 x g for 20 min at 4°C. Aliquots of plasma were frozen and 
kept at -80°C for later analyses of lipids, glucose, antioxidants, and bone and anti-inflammatory 
markers. The thymus, a fat pad of visceral adipose tis ue, uterus, spleen and liver were collected, 
weighed, and snap-frozen in liquid nitrogen. The int stines were removed and flushed with 
physiological saline for collection of cecal content.  
Bone Collection and Analyses   
The spine, tibia, and femur were collected and cleaned of adhering tissue for DXA and 
micro-computed tomography (µCT) analyses. Bone mineral density (BMD), area (BMA), and 
content (BMC) of the tibia and vertebrae were assessed with GE Lunar Piximus with Series 
Software version 1.4x (GE Medical Systems, LunarPIXI, Madison, WI). (Fitchburg, WI).  
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 The microarchitectural parameters of the tibia and vertebra were assessed using µCT 
(MicroCT40, SCANCO Medical, Switzerland). The proximal tibial metaphysis and mid-
diaphysis were used to analyze trabecular and cortical bone, respectively.  Scans of the tibial 
metaphysis were performed at a resolution of 2048 x 2048 pixels, (i.e. 6 µm each slice). Semi-
automated contours were placed beginning at 60 µm (10 slices) distal to the proximal growth 
plate and the volume of interest (VOI) included 882 µm (147 slices). The acquired images were 
analyzed at a threshold of 325 and a sigma and support of 1.2 and 2.0, respectively. Trabecular 
parameters evaluated included bone volume (BV), trabecular volume (TV), bone volume 
expressed per unit of total volume (BV/TV), trabecular number (TbN), trabecular thickness 
(TbTh), trabecular separation (TbSp) connectivity density (ConnDens) and structural model index 
(SMI).  Analysis of cortical bone was evaluated by analyzing a 52 slice VOI at the mid-point of 
the tibia.  Assessment of cortical bone included corti al porosity, thickness, area, and medullary 
area of the tibial mid-diaphysis.  The acquired images were analyzed at a threshold of 260 and a 
sigma and support of 0.8 and 1.0, respectively. 
Analyses of the spine were performed by acquiring images at a resolution of 1024 x 1024 
pixels, 80µm from the dorsal and caudal growth plates.  Similar to the tibial analysis, semi-
automated contours were placed to assess secondary spongiosa within the VOI. The images were 
analyzed at a threshold of 325, and a sigma and support of 1.2 and 2.0, respectively. 
Liver RNA Extraction and Quantitative Real-Time PCR  
RNA Extraction 
 Whole liver (n=6/group) was pulverized using liquid nitrogen and approximately 200 mg 
of liver was weighed out. The liver tissue was homogenized in nuclease-free tubes, using VWR 
PowerMAX mechanical homogenizer (VWR International, Radnor, PA) in RNA STAT60 (1 
mL/50 mg of tissue) (TEL-TEST, Inc., Friendswood, TX). Homogenate was then stored at room 
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temperature for 5 minutes to allow complete dissociation of nucleoprotein complexes and then 
200 µL of ACS grade chloroform (CHCl3) was added per 1 mL of RNA STAT60. The samples 
were vigorously shaken for about 15 seconds and then allowed to incubate at room temperature 
for about 3 minutes before centrifugation at 3,500 rpm (12,000 x g) at 4°C for 15 minutes. The 
upper aqueous layer was transferred to a new nuclease-free tube and ice-cold 0.5 mL ACS grade 
isopropanol was added for every 1 mL of RNA STAT60 used. The samples were then vortexed 
and stored at -80°C overnight to precipitate the RNA. Samples were thawed on ice the following 
day and centrifuged at 10,500 rpm for 10 minutes at 4°C. The supernatant was discarded and 
RNA pellet was washed with ACS grade 70% ethanol and centrifuged at 7,500 x g for 5 minutes 
at 4°C. The ethanol was discarded and the pellet was allowed to air dry for 5-10 minutes. The 
RNA pellet was re-suspended using diethylprocarbonate treated water (DEPC H2O) (0.5 mL for 
every 200 mg of tissue). A Nanodrop Spectrophotometer (Rockland, DE) was used to determine 
RNA concentration and purity (using the ratio of absorbance at 260 and 280 nm, A260/A280).  
cDNA Synthesis  
 RNase free DNase I (Roche Diagnostics, Indianapolis, IN) was diluted to 1/5 the original 
concentration using DEPC H2O. DNase reaction was set up in an 8-strip PCR tubes with flat caps 
(Axygen, INC., Union City, CA) on ice. Each reaction consisted of 0.32 µL DNase I (1/5 original 
concentration), 2 µg RNA, 3.36 µL of 25 mM MgCl2 (Roche Diagnostics, Indianapolis, IN), and 
DEPC H2O to a final volume of 20 µL. The samples were then placed in a TGradient 
Thermocycler (Biometra, Goettingen, Germany) set at 37°C for 30 minutes, 75°C for 10 minutes, 
and a 4°C soak cycle.  
 A mastermix consisting of 1µL Superscript II RTase (Invitrogen by Life Technologies, 
Carlsbad, CA), 20 µL 5X PCR buffer (Invitrogen by Life Technologies, Carlsbad, CA), 10 µL 
0.1M DTT (Invitrogen by Life Technologies, Carlsbad, CA), 20 µL 10mM dNTP mix (Roche 
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Diagnostics, Indianapolis, IN), 10 µL 0.8 mg/mL random hexamers (Roche Diagnostics, 
Indianapolis, IN), and 19 µL of DEPC H2O, was added to each sample for a total volume of 100 
µL. The samples were then placed once more in a TGradient Thermocycler set at 25°C for 10 
minutes, 42°C for 50 minutes, and 72°C for 10 minutes, and then a 4°C soak cycle, until samples 
were removed. The cDNA was stored at -20°C until further analysis.  
Real-Time PCR  
 Quantitative real time PCR was used to determine the presence and quantity of catalase 
(CAT), glutathione peroxidase 3 (GPX-3), interleukin-6 (IL-6), and tumor necrosis factor-α 
(TNF- α). Primers were prepared by combining 6.25 µL of the forward primer, 6.25 µL of the 
reverse primer, and 487.5 µL of DEPC H2O for a total concentration of 0.3 µM primer mix. 5.0 
µL of cDNA was analyzed using Power SYBR green chemistry (Applied Biosystems, Foster 
City, CA) on the Applied Biosystems 7300 Real Time PCR (Foster City, CA). All results were 
calculated by the comparative cycle number at threshold (CT) method, using cyclooxygenase 
(Cyclo) as the invariant control. The primers used for qPCR are shown in Table 3. 
Plasma Analyses  
The BioLis 24i clinical chemistry analyzer from Carolina Liquid Chemistries Corporation 
(Brea, CA) was used to determine plasma concentrations of glucose, non-esterified fatty acids 
(NEFA), total cholesterol, and triglycerides. Kits were purchased from Carolina Liquid 
Chemistries Corporation (Brea, CA) except for NEFA which was purchased from Wako 
Diagnostics (Richmond, VA) and the manufacturer’s instructions were strictly followed.  
The reaction of glucose, with the enzymes hexokinase and glucose-6-phosphate 
dehydrogenase produces NADH whose absorbance was measured at 340 nm after. NEFA is 
measured by a purple color produced by the oxidative condensation of 3-methyl-N-ethyl-N(β-
hydroxyethyl)-aniline (MEFA) and 4 aminoantipyrine. The reaction occurs in the presence of 
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added peroxidase and hydrogen peroxide that is produced as a byproduct of acyl-CoA and added 
acyl-CoA oxidase. Acyl-CoA is only produced in the pr sence of fatty acids plus added acyl-CoA 
synthetase, so therefore the color measured at 550 nm is directly proportional to the amount of 
NEFA present in the plasma.  
Cholesterol is measured by the addition of cholesterol esterase to the plasma sample to 
convert all cholesterol esters into free cholesterol and free fatty acids. Cholesterol then in the 
presence of oxygen and cholesterol oxidase forms cholest-4-ene-3-one and hydrogen peroxide. 
With the addition of peroxidase the hydrogen peroxide aids in the oxidative condensation of 4-
aminoantipyrine and p-hydroxybenzoate into quinoneimine, which can be measured at 546 nm. 
Triglycerides were measured using a technique that breaks it down to glycerol and fatty acids 
using microbial lipoprotein lipase. The glycerol then with the help of added ATP, glucokinase, 
and magnesium, is converted into glycerol-3-phosphate and ADP. In the presence of oxygen and 
glycerol-3-phosphate oxidase, the glycerol-3-phosphate is converted to dihydroxyacetone 
phosphate and hydrogen peroxide. The hydrogen peroxid  aids in the oxidative condensation of 
4-aminoantipyrine and HDCBS (3,5-dichloro-2-hydroxy-benzenesulfonicacidisodiumsalt) that 
produces a color that can be measured at 500 nm and is proportional to the amount of 
triglycerides in the plasma.  
 Plasma catalase and glutathione peroxidase activity were determined using commercially 
available kit from Cayman Chemical Company (Ann Arbor, MI) and results were read using the 
Synergy HT spectrophotometer (BioTek Instruments Inc., Winooski, VT). The catalase kit 
utilizes the peroxidatic function of catalase to determine the amount present in the sample. With 
the addition of methanol and hydrogen peroxide to the sample, the catalase produces 
formaldehyde. Formaldehyde reacts with the Purplad (4-amino-3-hydrazino-5-mercapto-1,2,4-
trizole) to turn a purple color and  the absorbance was read at 540 nm. Glutathione peroxidase 
(GPX) activity is measured indirectly by a coupled r action with glutathione reductase. 
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Hydroperoxide and reduced glutathione (GSH) produce oxidized glutathione (GSSG) in the 
presence of GPX. It is then recycled by glutathione reductase, which is accompanied by the 
oxidation of NADPH to NADP+ that reduces absorbance at 340 nm. The reduction in A340 is 
proportional to the amount of GPX present in the sample.  
Liver and Fecal Lipids  
Lipid extraction 
Feces and frozen liver tissue were ground, weighed into a filter paper and soaked in 25 
mL of a 2:1 solution of choloform:methanol (v/v) for three days. After three days of extraction, 
the filter paper was removed, and 8 mL of 0.73% saline solution was added to the 
choloroform:methanol and vortexed. The solution wasallowed to sit for a few minutes until the 
two layers were distinctly separated. The aqueous tp layer was aspirated off and the bottom 
organic layer was poured into pre-weighed, oven dried aluminum pan. The solution was air-dried 
and dried in the oven at 100°C for about an hour. The pans were allowed to cool in a dessicator 
and weighed for determination of lipid weight. A 2 mL aliquot was taken from the aspirated 
chloroform: methanol solution of the liver for cholesterol analysis.  
Determination of Liver Cholesterol 
A 2 mL aliquot of the chloroform:methanol solution (from the liver lipid analysis) was 
transferred into a screw cap vial to determine cholesterol content of the liver. Cholesterol 
standards and control serum were also put into separate vials and evaporated with nitrogen gas. 
The aliquot of the chloroform:methanol extract of the liver samples were also dried under 
nitrogen gas. After standards, samples and controls were dried, a saponification solution 
consisting of 15% KOH, ethanol, and pyrogallic acid, was added to the tubes. The tubes were 
heated in a rocking water bath at 90 °C for 20 minutes, briefly cooled, and 5 mL of distilled water 
and 10 mL of hexane were added. The tubes were vigorously mixed and the two phases were 
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allowed to separate. A 5 mL aliquot of the upper hexan  phase was separated into another screw 
cap vial and was allowed to evaporate again. Following this evaporation step, concentrated 
sulfuric acid, FeSO4  7H2O in 17.4 M (99.7%) acetic acid, and a mixture of acetone and ethanol 
(1:1, v/v) was added to the vials and were allowed to sit for 10 minutes to develop color. The 
results were read with a DU 800 Spectrophotometer (B ckman Coulter, Inc., Pasadena, CA). The 
concentration of cholesterol in the sample was obtained from the standard curve.  
Statistical Analyses  
 Statistical analyses involved computation of means and standard deviation (SD) for each 
of the treatment groups using SAS version 9.3 (SAS Institute, Cary, NC). Analysis of variance 
and least square means were calculated using the general linear model procedure and the means 
were compared using Fisher’s least significant difference for comparing groups. Differences were 












Table 1. Diet Composition 






 g/kg Diet 
Watermelon g/kg 
Diet 
 10 100 250 
CARBOHYDRATE      
Total 721 726.847 721.102 711.507 
Cornstarch 466 456.397 377.572 246.177 
Sucrose 100 107.33 107.33 107.33 
Dextrinized 
Cornstarch 
155 155 155 155 
Watermelon (81.2%) - 8.12* 81.2* 203* 
PROTEIN     
Total 140 140 140 140 
Casein 140 139.14 131.39 118.48 
Watermelon (8.61%) - 0.861* 8.61* 21.525* 
FAT     
Total 40 40 40 40 
Soybean Oil 40 39.768 37.68 34.2 
Watermelon (2.32%) - 0.232* 2.32* 5.8* 
FIBER     
Total 50 50 50 50 
Cellulose 50 49.897 48.97 47.425 
Watermelon (1.03%) - 0.103* 1.03* 2.575* 
VITAMIN MIX 
(AIN 93VX) 
10 10 10 10 
MINERAL MIX     
Total  35 35 35 35 
Mineral Mix (Ca-P 
Def; TD 98057) 
13.4 13.4 13.4 13.4 
Calcium Carbonate 
(CaCO3); 40.04% Ca 




- 0.00914* 0.0914* 0.2285* 
Calcium Phosphate, 
dibasic  




- 0.0253* 0.253* 0.6325* 
Sucrose 6.7 6.840 7.250 7.920 
CHOLINE 
BITARTRATE 
2.5 2.5 2.5 2.5 
L-CYSTEINE 1.8 1.8 1.8 1.8 
TERT-BUTYLYL-
HYDROQUINONE 
0.008 0.008 0.008 0.008 













Moisture %  9.05 13.8 13.3 14.0 
Protein % 12.5 11.7 10.2 12.2 
Fat % 4.55 4.47 4.49 4.25 
Fiber-Crude %  2.97 2.99 3.31 3.88 
Ash % 2.31 2.07 2.19 2.84 
Calcium % 0.496 0.465 0.492 0.489 
Phosphorus % 0.303 0.290 0.286 0.281 
Carbohydrate (by 
calc.) % 
71.6 68.0 69.8 66.7 
Calories (by calc.) 
kcal/100g 
377 359 360 354 




Table 3. List of Primer Sequences used for Real-Time PCR   
Symbol Name Primer Sequence Accession Number 
Cyclo Cyclophilin  For-5`tggagagcaccaagacagaca 
Rev-5`tgccggagtcgacaatgat NM_011149 














The criteria used for primer design/validation is the amplicon must span an intron, template 









Weekly Body Weights, Food Intake, and Tissue Weights  
All mice had similar body weights at the start of the dietary treatment (Table 4). After 
only one week of treatment, OVX mice receiving the two high doses of watermelon (OVX-WM 
10% and 25%) had higher body weights compared to all he other treatment groups (Figure 1). 
By week two, all WM-fed groups had significantly hig er weights than the groups fed the control 
diet (Sham-control, OVX-control, and OVX-ALN-Control). The body weight of the WM-fed 
groups continued to be significantly higher throughout the treatment period, despite having lower 
food and caloric intake compared to the Sham-control and OVX-control (Table 4). Among the 
watermelon groups, the mice that were given the 25%dose had the highest body weight at the 
end of the 12 week dietary treatment.  
As expected, uterine weights were highest for the sham group and all the other OVX 
groups had similar uterine weights (Table 4). The sham and OVX alendronate control (OVX-
ALN- control) fed groups had the lowest liver weight. There was no significant difference in liver 
weight between WM fed groups and the OVX-control grup. Consistent with the final body 
weight, visceral adipose tissue weight was significantly higher in OVX-WM 25% compared to all 
other groups. OVX-WM 10% and WM1% also had higher visceral adipose tissue weights
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compared to mice fed the control diet (OVX-control, Sham-control, and OVX-ALN-Control) but 
lower than the OVX-WM 25% group.  
Whole Body Composition, and Tibia and Lumbar PIXImus Analysis  
Percent whole body fat analyzed by x-ray absorptiometry is consistent with the weight of 
the isolated visceral adipose tissue (Table 5). The WM fed groups had higher percent body fat 
and lower percent lean mass compared to the mice fed the control diet. Additionally, WM fed 
groups (particularly the 25% WM) had lower whole body bone mineral BMD, BMC and total 
area than Sham-Control and OVX-ALN-Control groups. The 10% WM group had whole body 
BMD, BMC and BMA that were statistically similar tohe OVX-Control. The Sham-Control 
group had the highest BMD, BMC, and area followed by the OVX-ALN-Control group (Table 
5).  
Isolated bone (i.e., tibia and spine) was also analyzed by x-ray absorptiometry. Tibial 
bone area was highest in the OVX-ALN and OVX-WM 1% groups and lowest in the OVX-25% 
WM group (Table 5). Tibial BMC was also highest in the OVX-ALN, which is statistically 
similar to the Sham-Control group. Among the WM-fed groups, the OVX-WM25% group had 
the lowest tibial BMC while the OVX-WM1% group had the highest tibial BMC but it is 
statistically similar to the OVX-control group and. The pattern for tibial BMD is similar to the 
tibial BMC with the OVX-ALN and Sham-Control group having the highest while the WM 25% 
group having the lowest tibial BMD (Table 5 and Figure 2). 
Unlike the tibia, lumbar BMA were not statistically different among all the treatment 
groups (Table 5). Lumbar BMC and BMD were statistically similar in the sham and OVX-ALN 
groups, which were also significantly higher than all the other OVX groups. There were no 
significant differences in lumbar BMC and BMD in all OVX-WM and OVX-control fed groups 
(Figure 2, Table 5). 
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Tibial Trabecular and Cortical Bone Microarchitectu re (Table 6) 
 Tibial trabecular bone volume over total volume (BV/T ) values were significantly 
different between the groups. BV/TV was highest (p<0.05) for OVX-ALN-control followed by 
the Sham-control group. All OVX-WM groups and the OVX-control group have similar BV/TV 
and they were lower compared to both the OVX-ALN-contr l and Sham-control groups.  
Tibial trabecular bone connectivity density (Conn. D.) was highest for the OVX-ALN-
control group and all the other OVX groups as well as the Sham-control group were similar. 
Structural model index (SMI) was highest for the WM 10% group which was statistically similar 
to all the other WM groups. SMI was lowest for the OVX ALN control group, which was similar 
to the Sham-control. SMI value of the OVX-1% and 25% WM as well as OVX-control groups 
was similar to the Sham-control group. 
All the WM groups and the OVX-control have similar tibial trabecular number (Tb.N) 
which was lower than the Sham-control and OVX-ALN control groups. Trabecular thickness 
(Tb.Th) was highest in the Sham control group, which was statistically similar to OVX- control, 
OVX-WM 1% and 10% groups. The OVX-ALN-control group had the lowest Tb.Th value. 
Trabecular separation (Tb.Sp) was increased in all the WM and OVX control groups and lowest 
in OVX-ALN control group. The WM 1% and 10% as well as the OVX control groups have 
similar DA values which were lower than the WM 25%, Sham-control, and OVX-ALN control 
groups.  
 The OVX-control and all doses of WM have similar cotical area, which was lower than 
the Sham-control and OVX-ALN groups. There were no significant differences between groups 
for cortical BV/TV. There were also no significant differences observed for medullary area and 




Lumbar (L4) Trabecular Bone Microarchitecture (Tabl e 7) 
  The BV/TV was highest in the OVX-ALN group as expected due to treatment. Sham 
control group had the second highest BV/TV values. The lowest BV/TV belonged to the WM 
25% groups and this was comparable to WM 1% and OVX-control groups. WM10% was 
significantly higher than the OVX-control group. Betw en the three WM groups, WM 10% had 
the highest BV/TV, about 58% greater than WM 25% and bout 47.5% higher, although not 
significant, than WM 1%.  
 Similarly, Tb.N. and Tb.Th were highest and Tb.Sp was lowest in WM10% compared to 
all watermelon groups, which was most likely responsible for the increased BV/TV in WM10% 
group. Additionally, WM10% was the only WM group tha  was comparable to the Sham control 
group for Tb.N. and Tb.Sp, although also similar to OVX-control. WM10% was able to prevent 
decrease in connectivity density due to OVX and wassignificantly higher than WM1%, WM25% 
and OVX-control groups. WM 10% also had the lowest SMI between WM1%, WM25% and 
OVX-control although not significant. However between these groups, the SMI value for 
WM10% was the only one comparable to sham control. There is no statistically significant 
difference in DA values for the lumbar trabecular bone among all the treatment groups. 
Plasma Lipids, Glucose, and Antioxidant Enzymes (Table 8) 
No significant differences were observed in plasma triglycerides and non-esterified fatty 
acids in all groups. Plasma cholesterol concentration was highest in the OVX-WM 1% group and 
statistically similar to the WM 25% and OVX-control groups. The WM-10% group has plasma 
total cholesterol that is similar to the Sham contrl and OVX-ALN groups. Plasma glucose 
concentration was highest in the OVX-WM 25% group and lowest in the Sham-control group. 
The plasma glucose concentrations of the OVX-WM 1% and 10% were comparable to the OVX-
ALN-control and OVX-control groups. 
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Catalase and GPX activity were both assessed in the plasma. There were no significant 
differences found in either of the antioxidant enzymes. However, GPX activity tended to be 
increased in the WM10% fed group, while being the lowest in the OVX-WM1% group. 
Fecal and Liver Total Lipids and Liver Cholesterol (Table 9) 
  All OVX groups have higher liver total lipids compared to the Sham-control group. 
However, the WM 10% and 25%-fed groups have liver total lipds similar to the Sham-control 
group. There was no significant difference in liver cholesterol. Fecal total lipid was highest in 
OVX-WM10% group and lowest in the OVX-control group. 
Liver Relative mRNA Abundance of Inflammatory Cytokines and Antioxidant Enzymes 
(Figures 3&4) 
 The mRNA abundance in the liver of the antioxidant e zymes catalase (CAT) and 
glutathione peroxidase 3 (GPX-3) and inflammatory cytokines interleukin-6 (IL-6) and tumor 
necrosis factor-α (TNF-α), were all quantified. The WM10% fed group had the highest liver gene 
expression of catalase. All the remaining groups have similar gene expression of catalase in the 
liver. There were no significant differences found i  the liver gene expression of glutathione 











































































































































































































Figure 1.  
Comparison of weekly body weights between groups throughout the 12-week treatment period. Asterisks denote significant difference between 






















































































































































































Values are mean ± SD; In a row, values that do not share the same superscript letter are 
significantly different (p<0.05); BMA= Bone Mineral Area; BMD= Bone Mineral Density; 











Figure 2. Comparison of bone mineral content of tibia and lumbar trabecular 
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Table 6. Proximal Tibial Metaphysis and Tibial Mid-Diaphysis 
 
 Sham 



















Proximal Tibial Metaphysis (Trabecular Bone) 





























































































































































Values are mean ± SD; In a row, values that do not share the same superscript letter are 
significantly different (p<0.05). TV= Total Volume; BV= Bone Volume; Conn.D= Connectivity 
Density; SMI= Structural Model Index; Tb.N.=Trabecular Number, Tb.Th.= Trabecular 






































































































































Values are mean ± SD; In a row, values that do not share the same superscript letter are 
significantly different (p<0.05). TV= Total Volume; BV= Bone Volume; Conn.D= Connectivity 
Density; SMI= Structural Model Index; Tb.N.=Trabecular Number, Tb.Th.= Trabecular 




















































































































































Values are mean ± SD; In a row, values that do not share the same superscript letter are 

































































































Values are mean ± SD; In a row, values that do not share the same superscript letter are 
















Figure 3. Comparison of liver relative mRNA abundance of inflammatory cytokines in OVX-
ALN-control, OVX-Control, WM1%, WM105 and WM25% relative to Sham control group (set 
at 1.0). CT values for Sham control group are listed b low the respective gene.Values are mean ± 
SEM; Bars that do not share the same superscript letter are significantly different (p<0.05). IL-6= 
interleukin 6, TNF-α= tumor necrosis factor alpha. Cyclo= Cyclophilin was used as the invariant 














































Figure 4. Comparison of liver relative mRNA abundance of antioxidant enzymes in OVX-ALN-
control, OVX-Control, WM1%, WM105 and WM25% relative to Sham control group relative to 
Sham control group (set at 1.0). CT values for Sham control group are listed below the respective 
gene. Values are mean ± SEM; Bars that do not share t e same superscript letter are significantly 
different (p<0.05). GPX-3= glutathione peroxidase 3. Cyclo= Cyclophilin was used as the 




















































The purpose of the present study was to determine if watermelon, due to its antioxidant 
and anti-inflammatory properties, would be able to prevent bone loss in ovariectomized (OVX) 
mice. It has been shown in previous studies that this animal model is appropriate for studying 
postmenopausal osteoporosis (103, 104). Additionally, this animal model has been used for 
investigating the effects of dietary interventions i  preventing or delaying post-menopausal bone 
loss or osteoporosis. Rendina et al. used an OVX model to demonstrate the effects of varying 
doses of dried plum on ovariectomy-induced bone loss and found that a high dose of dried plum 
supplementation prevented the loss of spine BMD and BMC (105). Mori-Okamoto et al., used 
OVX mice to demonstrate that pomegranate extract was able to increase bone volume and 
trabecular number, and decrease trabecular separation (106). Studies have also been done using 
compounds found in fruits and vegetables such as hesperidin and sarsasapogenin to demonstrate 
their beneficial effects on bone parameters of OVX mice (107, 108). These studies are a few 
examples from the literature the show positive effects of dietary interventions on bone with an 
OVX mice model.  
Our main objective was to determine if dietary waterm lon supplementation would 
prevent the OVX-induced decrease on BMD, BMC, BMA and bone microarchitecture. 
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Watermelon was selected because it contains nutrients that have antioxidant and anti-
inflammatory activity, including lycopene, vitamin C, β-carotene, citrulline, and cucurbitacin E 
(82, 83). Lycopene, vitamin C, and β-carotene have been shown to have antioxidant activity that 
improves bone health (84, 88, 97). Cucurbitacin E has also been implicated in the inhibition of 
oxidation in cells, but there is no direct link to b ne health (94). Finally citrulline, an amino acid 
unique to watermelon, is a precursor for arginine, which is important in macrophages to mediate 
inflammatory responses (28). However, similar to cucurbitacin E, to our knowledge there is no 
research has been published that connects the mechanism of action citrulline to bone health. We 
hypothesized that these components working together could have a positive effect on bone and 
reduce bone loss in OVX mice.  
We observed that there were no significant differences between the tibial and lumbar 
BMD of the OVX-control groups and the WM fed groups. Additionally, the whole body BMD 
values were significantly lower in the WM1% and WM25% groups compared to OVX-control, 
but WM 10% was comparable to that of OVX-control. The combined BMD values of tibia, 
lumbar and whole body suggest no possible benefit of watermelon in this parameter. A possible 
explanation for this could be that the weight gain in the WM 25% group due to increased 
adiposity, was counteracting any positive effects from the bioactive components in watermelon. 
Previous research has demonstrated that obesity increases inflammatory cytokine and oxidative 
stressors and could play a role in decreasing bone mass (109, 110). We also observed a significant 
increase in plasma glucose of the WM25% fed group, which could suggest insulin resistance as a 
result of the adiposity (111). WM1% may not have had enough watermelon to counteract the 
bone loss while WM25% group may have had too much of t e watermelon, causing the increased 
adiposity. WM10% seemed to maintain more of a balance with the watermelon’s positive and 
negative side effects. These results are consistent with other studies (124).  Lucas et.al., also 
found the lower dose of fruit supplementation more beneficial than a higher one. They discovered 
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that the high fat diet plus 1% mango showed higher whole body, tibial, and vertebral BMD 
compared to high fat alone, but high fat diet plus 10% mango did not produce these same effects 
(124). 
The µCT analyses conducted also produced a similar trend that shows WM10% has a 
positive effect on a few of the bone parameters measur d. Based on previous research, we 
predicted that the tibia and lumbar were shown to be practical sites to assess changes in bone 
parameters using µCT (104, 112). We observed slight positive outcomes with the WM10% fed 
groups in the lumbar trabecular bone, although the tibial trabecular and cortical bones were not 
affected. In women with osteoporosis, vertebral fractures are very common and generally occur 
below the mid-thoracic region (113). Nearly 3/4ths of all vertebral fractures occur during routine 
daily activities, such as bending over and lifting objects, and only about 1/3rd of those come to 
medical attention and prompt preventative treatments (114). Analyses of the L4 region of the 
vertebra showed that the WM10% group was able to rest  connectivity density to the levels of 
the sham-control group, despite the increase in body weight and body fat. As stated in the results, 
the WM10% group also had comparable BV/TV, structure model index, and trabecular separation 
as the sham control group; however, it was also comparable to the OVX-control group. This 
suggests that WM10% had intermediate effect in resto ing these parameters. WM10% therefore 
might be the most suitable option for restoring bone parameters from the three doses 
administered.  
In order to understand the mechanism by which WM10% had a positive effect on bone, 
anti-inflammatory and antioxidant markers were asses ed in plasma and liver. Increased 
inflammation and oxidative stressors both have been associated with the onset and progression of 
postmenopausal osteoporosis (14, 16). We decided to observe systemic changes in these 
parameters so plasma was used to assess the activity of antioxidant enzymes, and liver mRNA 
was used to assess gene expression of both antioxidant enzymes and inflammatory cytokines.  
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The inflammatory cytokines chosen were TNF-α and IL-6, both of which increase 
osteoclastogeneis (14). Osteoclast production and activity is largely driven by cytokines, 
especially TNF-α, which works by increasing RANK-L production, increasing RANK in 
osteoclast precursors, as well as increasing responsiveness of RANK to RANK-L (9). Although 
IL-6 has receptors on both osteoblasts and osteoclasts, its main physiological effects occur 
through other cytokines. IL-6 stimulates IL-1 releas  that increases osteoclast formation as well 
as mediates the stimulatory effects of TNF-α on osteoclast precursors (31). We did not see any 
significant changes with the inflammatory cytokines, TNF-α and IL-6, in liver mRNA abundance. 
One of the reasons this could have occurred was becaus  there was a lot of variability with the 
TNF-α data in each group. Although not significant, IL-6 did not display this variation and 
mRNA levels seemed to decrease in the WM fed groups. 
We also assessed systemic antioxidant expression in plasma and liver. Lean and 
colleagues demonstrated that the administration of antioxidants, ascorbate or N-acetyl- cysteine 
(precursor to glutathione), prevented OVX- induced bone loss in mice (115). Similarly, Rao et. 
al., found that lycopene intake in postmenopausal women decreased protein oxidation and lipid 
peroxidation while also decreasing bone resorption (26). Catalase and GPX are both responsible 
for neutralizing reactive oxygen species, specifically hydrogen peroxide, which is essential for 
bone loss due to estrogen deficiency and osteoclastgenesis (116). Furthermore, GPX-3 is highly 
abundant in the plasma, and therefore liver mRNA abundance of GPX-3 specifically was 
observed (117). Liver Catalase mRNA was significantly higher in the WM10% fed groups 
compared to all other groups and was comparable to the WM25% group. However when 
analyzing the plasma we observed no significant difference in catalase and GPX activity between 
the groups. These results were consistent with the results from our bone analyses, suggesting that 
WM10% may be the optimal done to prevent bone loss through increased antioxidant activity.  
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In the current study, we demonstrated that our OVX model had increased bone loss as 
evidenced by decreased BMD and compromised µCT architecture. The OVX model is also 
expected to gain body weight as supported in other studies (103, 118).  However in the present 
study, the OVX mice fed 10% and 25% watermelon diets had significantly increased body 
weights and body fat, by the completion of week 1, compared to OVX-control. Food intake 
remained similar throughout the study between the groups and diet compositions were isocaloric, 
isonitrogenous and had the same calcium and phosphorus c ncentrations.  Possible explanations 
for this change in body composition could be related to the components in the watermelon 
altering the gut microbiota that could possibly be promoting weight gain. Greiner t.al, have 
demonstrated that alterations in gut microbiota can increase obesity and promote insulin 
resistance (119). Additionally, Laparra et.al, have discussed that phytochemicals from functional 
foods that are used by the bacteria to produce secondary metabolites, are also able to influence 
growth and activity of specific intestinal bacteria (120). This leads to the possibility that there is 
an alteration of gut bacteria in the C57BL/6 female mice through the bioactive components of 
watermelon, especially those that exist in a larger quantity such as lycopene. A study done by 
Kim et.al, observed similar effects and found that with increased doses of lycopene, there was 
increased weight gain in female B6C3F1 mice, a cross between C57BL/6 and C3H mice, 
however in a chemoprevention study rather than an OVX model (121). These explanations on the 
effect of watermelon on body weight and composition are all speculative and warrants further 
investigation. 
The weight gain observed in the watermelon-fed mice prompted us to examine lipid 
parameters. As expected all OVX groups had increased proportions of fat in the liver and sham 
control had the lowest which was comparable to watermelon 10% and 25%. This suggests that 
watermelon prevented the accumulation of fat in the liver. When feces were analyzed, WM 
groups had the highest fecal fat content, however, this was not significantly different from ALN-
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control. Previous research has shown that ovariectomy causes hyperlipidemia (104, 122), 
however we did not observe that in our study with our plasma cholesterol analysis. Although not 
significantly different, the WM fed groups seemed to have lower liver cholesterol compared to 
the OVX and sham, which points towards another possible benefit of watermelon, but this needs 
to be further explored. 
Limitations 
Although WM10% seems promising, it is necessary to keep in mind the limitations of 
this study. Bones could have also been used to assess antioxidant enzymes to observe a more 
local effect of the watermelon rather than using liver. Lean et.al., measured glutathione and 
glutathione reductase in OVX mice, and found that leve s were unchanged in liver and spleen 
compared to sham, however, they were decreased in the bone marrow (115), which may explain 
why glutathione peroxidase was not significantly different in liver mRNA expression and plasma 
activity. Another limitation is that the data obtained from an animal model may not be 
translatable to humans. The mouse genome is about 85% similar in sequence to the human 
genome, but the 15% difference could translate into countless differences (122). Additionally, the 
Mus musculus (house mouse) only has a lifespan of about two to three years in a protected, well-
controlled environment (123). The mouse model should be used as a basis for furthering research 
with watermelon and conducting a human study as the next step.  
Conclusion  
In conclusion, our data indicates that watermelon, in a moderate amount, might be a 
suitable dietary option for maintaining skeletal health. Possible components in watermelon that 
could be responsible for these benefits include lycopene, vitamin C and beta-carotene as 
antioxidants, and citrulline and cucurbitacin E as anti-inflammatory agents. There is an unknown 
mechanism by which watermelon is increasing weight gain in OVX mice, which needs to be 
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further explored. Such research could include experiments on the components in watermelon, 
such as lycopene, and alterations in gut microbiota of OVX mice that are influencing weight gain, 
and if that would also exhibit the same effect in humans. In this study, we found that with high 
doses of watermelon, the beneficial effects of the bioactive components could possibly be 
counteracted by increased inflammation and oxidation due to the increased adiposity. A possible 
way to explore this would be to design a WM5% and WM15% diet and examine if the effects 
have a range in which they provide maximum benefit, and examine other bones in the OVX mice 
to see if the watermelon is exhibiting its effects el ewhere. Finally, watermelon could also 
possibly have an effect of reducing cholesterol in OVX mice as it was observed in this study, 
despite the increased body weight, and the follow up experiment could also take into 
consideration circulating cholesterol levels. Although more research is needed in this area, 
watermelon in moderate amounts, along with a variety of other fruits and vegetables, should be 
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